NOVO NORDISK A/S
Commented by Fabian Lorenz on February 10th, 2026 | 11:20 CET
SHARE PRICE FIREWORKS! RENK and Novo Nordisk shares take off! Vidac Pharma next?
Share price fireworks at Novo Nordisk yesterday. The battered pharmaceutical stock rose by around 6%. After a weak outlook and the prospect of increasing competition for its blockbuster product, there was some positive news for a change: a competing product is not permitted to be sold in the key US market. RENK shares also rose significantly yesterday. Since last Thursday, the share price has risen by over 10%. Positive analyst commentary is increasing. Vidac Pharma is poised for a rally. The biotech company is working on an attractive oncology pipeline, has once again secured an important patent, and the stock is receiving tailwinds from its Xetra listing. Analysts see the potential for a multiplication.
Read
Commented by Armin Schulz on February 6th, 2026 | 07:00 CET
Almonty Industries Surges, Novo Nordisk and PayPal Correct: Where Are the Entry Points?
The stock market is increasingly divided. While mining stocks are benefiting from geopolitical upheavals and the strategic race for raw materials, established market heavyweights are being punished at the slightest disappointment. This shift reflects the growing limits of globalization. Today, resilience beats efficiency. Three very different companies illustrate this new environment: tungsten producer Almonty Industries, pharmaceutical giant Novo Nordisk, and payment service provider PayPal. We analyze the current situation.
Read
Commented by Fabian Lorenz on February 5th, 2026 | 08:25 CET
Almonty shares are skyrocketing! Novo Nordisk shares are plummeting! And what is Hensoldt doing?
Almonty shares gained over 17% on the Nasdaq on Tuesday. The largest Western tungsten producer is likely to benefit from the US government's build-up of strategic reserves of critical raw materials. In addition, analysts have significantly raised their price target and expect Almonty to achieve a net margin of around 50% in 2027. Novo Nordisk, on the other hand, plummeted by over 17% yesterday. The pharmaceutical company has once again shocked the stock market. It expects declining revenue and profits for the current year. And what about Hensoldt? The stock is treading water, but analysts see potential for price gains. In addition, the company has landed an order worth hundreds of millions of euros.
Read
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on January 26th, 2026 | 07:30 CET
Biotech and life sciences are booming, and now Mercosur is joining the fray! Bayer, MustGrow, Novo Nordisk, and BioNxt Solutions in focus
The 2026 stock market year has a few surprises in store for investors. In addition to a quick resolution to the Greenland dispute, the Mercosur trade agreement with several South American countries is also moving forward. This agreement is particularly significant for the agricultural industry. This global sector of human supply is increasingly characterized by regulatory pressure, which is effectively ending the use of many synthetic pesticides and fertilizers. This development is forcing established agricultural companies to integrate effective biological alternatives into their portfolios faster than planned. In this environment, MustGrow Biologics is positioning itself as a strategic technology provider whose active ingredients have already been validated by leading market players. An expanded sector view also covers the life sciences industry with the protagonists Bayer, Novo Nordisk, and BioNxt. Up 50% in just a few weeks, here they are!
Read
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read
Commented by Armin Schulz on January 8th, 2026 | 07:05 CET
How to benefit from the healthcare industry's comeback in 2026: Novo Nordisk, Vidac Pharma, and Pfizer in focus
After a disappointing year for investors in the pharmaceutical and biotech industries, the tide is now turning decisively on the stock market for these stocks. Political clarity, a return to major acquisitions, and groundbreaking clinical data are laying the foundation for a sustainable comeback. This new optimism is opening up concrete opportunities for strategic investments. Three companies exemplify these promising drivers: Novo Nordisk, Vidac Pharma, and Pfizer.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Fabian Lorenz on December 30th, 2025 | 07:10 CET
Gold gem, AI fantasy, and pharmaceutical giant! Which stock will take off in 2026? TeamViewer, Novo Nordisk, Laurion Mineral Exploration
The gold rally is simply unstoppable. But the big producers such as Barrick Mining and Newmont have already run their course. However, there are always undiscovered gold gems to be found. LAURION Mineral Exploration is one of them. The management team made a convincing case at an investor conference, and the stock is unlikely to remain so cheap for long. Novo Nordisk staged a small year-end rally. Nevertheless, the slide in the share price during the current year has been painful. Can the stock pick up speed again in 2026? TeamViewer is one of the disappointments of 2025 in Germany. Will AI fantasy bring the German software company's stock back into an upward trend?
Read
Commented by Fabian Lorenz on December 23rd, 2025 | 07:35 CET
Big news at the turn of the year! Nordex, Novo Nordisk, AJN Resources!
Is now the time for gold explorers? The price of gold remains firmly above USD 4,300 per ounce, and shares of gold producers are performing well, perhaps even a little too well. Investors looking to continue participating in the gold bull market may therefore turn their attention to exploration companies. One such candidate is AJN Resources. The stock has already moved higher, yet still offers upside potential, supported by takeover speculation. Novo Nordisk has submitted an application for US approval following convincing Phase 3 results, a step that would be strategically significant for the Company. Meanwhile, Nordex remains one of the positive surprises of 2025, having reported another major order. The key question now is how far can the rally go?
Read